NU578 Exam 5 Practice Questions & Answers
(Verified Updated)
This comprehensive study guide covers the core domains tested
on NU578 Exam 5, aligned with the 2026–2027 curriculum at
the University of South Alabama. It includes original practice
questions with detailed rationales, organized by topic:
Antibacterials, Antivirals, Antifungals, and Chemotherapy
Agents.
The exam covers 75 total questions, multiple choice and select
all that apply, with content areas including anti-infectives,
complex disease management, advanced pharmacology clinical
decision-making, and professional role & ethics
Section 1: Antibacterials
1.1 Mechanisms of Action & General Principles
Q1. PCN and Cephalosporins share which mechanism of action?
A. Inhibition of bacterial protein synthesis
B. Inhibition of bacterial cell wall synthesis or activation of
enzymes that disrupt the cell wall
C. Disruption of cell membrane permeability
D. Inhibition of DNA and RNA synthesis
,Answer: B
Rationale: Penicillins and cephalosporins are beta-lactam
antibiotics that inhibit bacterial cell wall synthesis by binding to
penicillin-binding proteins (PBPs). They weaken the cell wall by
inhibition of transpeptidases and disinhibition (activation) of
autolysins, causing bacteria to take up excessive amounts of
water and rupture (bactericidal). They are only effective against
bacteria that are undergoing growth and division.
Q2. A nurse practitioner is prescribing antibiotics for a patient
with a confirmed bacterial infection. Which principle should
guide the selection of the most appropriate antibiotic?
A. Choose the broadest-spectrum agent available to ensure
coverage
B. Select the antibiotic with the lowest cost regardless of
spectrum
C. Use culture and sensitivity results to target the specific
pathogen
D. Prescribe the antibiotic the patient requests based on prior
experience
Answer: C
Rationale: Culture and sensitivity testing identifies the specific
pathogen and its antibiotic susceptibility, allowing for targeted
therapy. This approach minimizes resistance development,
reduces adverse effects, and improves outcomes. Broad-
,spectrum agents should be reserved for empiric therapy when
pathogens are unknown. Cost and patient preference are
considerations but should not override evidence-based
selection.
Q3. When educating a patient about antibiotic adherence,
which statement by the patient indicates understanding of
resistance prevention?
A. "I'll stop taking the antibiotic once I feel better to avoid side
effects."
B. "I should save leftover antibiotics for future infections."
C. "I need to take the full course exactly as prescribed, even if
symptoms improve."
D. "I can share my antibiotics with family members who have
similar symptoms."
Answer: C
Rationale: Completing the full prescribed course ensures
eradication of the pathogen and prevents survival of resistant
strains. Stopping early allows partially resistant bacteria to
proliferate. Saving or sharing antibiotics is dangerous, promotes
resistance, and violates prescribing regulations.
Q4. Rifampin, metronidazole, and fluoroquinolones (Cipro)
share which mechanism of action?
A. Inhibition of cell wall synthesis
B. Inhibition of protein synthesis
, C. Inhibition of bacterial synthesis of DNA and RNA or
disruption of DNA function
D. Disruption of cell membrane permeability
Answer: C
Rationale: Rifampin, metronidazole, and fluoroquinolones all
inhibit bacterial synthesis of DNA and RNA or disrupt DNA
function. This is a key distinguishing mechanism from cell wall
inhibitors (penicillins, cephalosporins) and protein synthesis
inhibitors (macrolides, tetracyclines).
Q5. What is selective toxicity in antimicrobial therapy?
A. The ability of a drug to kill all bacteria
B. The ability of a drug to injure a target cell or organism
without injuring other cells or organisms in intimate contact
with the target
C. The ability of a drug to cause allergic reactions
D. The ability of a drug to be excreted unchanged
Answer: B
Rationale: Selective toxicity is the ability of an antibiotic to kill
or suppress microbial pathogens without causing injury to host
cells. This is achieved through disrupting the bacterial cell wall,
inhibiting an enzyme unique to bacteria, or disrupting bacterial
protein synthesis.
Q6. What is a superinfection?
A. An infection that occurs before antibiotic therapy
(Verified Updated)
This comprehensive study guide covers the core domains tested
on NU578 Exam 5, aligned with the 2026–2027 curriculum at
the University of South Alabama. It includes original practice
questions with detailed rationales, organized by topic:
Antibacterials, Antivirals, Antifungals, and Chemotherapy
Agents.
The exam covers 75 total questions, multiple choice and select
all that apply, with content areas including anti-infectives,
complex disease management, advanced pharmacology clinical
decision-making, and professional role & ethics
Section 1: Antibacterials
1.1 Mechanisms of Action & General Principles
Q1. PCN and Cephalosporins share which mechanism of action?
A. Inhibition of bacterial protein synthesis
B. Inhibition of bacterial cell wall synthesis or activation of
enzymes that disrupt the cell wall
C. Disruption of cell membrane permeability
D. Inhibition of DNA and RNA synthesis
,Answer: B
Rationale: Penicillins and cephalosporins are beta-lactam
antibiotics that inhibit bacterial cell wall synthesis by binding to
penicillin-binding proteins (PBPs). They weaken the cell wall by
inhibition of transpeptidases and disinhibition (activation) of
autolysins, causing bacteria to take up excessive amounts of
water and rupture (bactericidal). They are only effective against
bacteria that are undergoing growth and division.
Q2. A nurse practitioner is prescribing antibiotics for a patient
with a confirmed bacterial infection. Which principle should
guide the selection of the most appropriate antibiotic?
A. Choose the broadest-spectrum agent available to ensure
coverage
B. Select the antibiotic with the lowest cost regardless of
spectrum
C. Use culture and sensitivity results to target the specific
pathogen
D. Prescribe the antibiotic the patient requests based on prior
experience
Answer: C
Rationale: Culture and sensitivity testing identifies the specific
pathogen and its antibiotic susceptibility, allowing for targeted
therapy. This approach minimizes resistance development,
reduces adverse effects, and improves outcomes. Broad-
,spectrum agents should be reserved for empiric therapy when
pathogens are unknown. Cost and patient preference are
considerations but should not override evidence-based
selection.
Q3. When educating a patient about antibiotic adherence,
which statement by the patient indicates understanding of
resistance prevention?
A. "I'll stop taking the antibiotic once I feel better to avoid side
effects."
B. "I should save leftover antibiotics for future infections."
C. "I need to take the full course exactly as prescribed, even if
symptoms improve."
D. "I can share my antibiotics with family members who have
similar symptoms."
Answer: C
Rationale: Completing the full prescribed course ensures
eradication of the pathogen and prevents survival of resistant
strains. Stopping early allows partially resistant bacteria to
proliferate. Saving or sharing antibiotics is dangerous, promotes
resistance, and violates prescribing regulations.
Q4. Rifampin, metronidazole, and fluoroquinolones (Cipro)
share which mechanism of action?
A. Inhibition of cell wall synthesis
B. Inhibition of protein synthesis
, C. Inhibition of bacterial synthesis of DNA and RNA or
disruption of DNA function
D. Disruption of cell membrane permeability
Answer: C
Rationale: Rifampin, metronidazole, and fluoroquinolones all
inhibit bacterial synthesis of DNA and RNA or disrupt DNA
function. This is a key distinguishing mechanism from cell wall
inhibitors (penicillins, cephalosporins) and protein synthesis
inhibitors (macrolides, tetracyclines).
Q5. What is selective toxicity in antimicrobial therapy?
A. The ability of a drug to kill all bacteria
B. The ability of a drug to injure a target cell or organism
without injuring other cells or organisms in intimate contact
with the target
C. The ability of a drug to cause allergic reactions
D. The ability of a drug to be excreted unchanged
Answer: B
Rationale: Selective toxicity is the ability of an antibiotic to kill
or suppress microbial pathogens without causing injury to host
cells. This is achieved through disrupting the bacterial cell wall,
inhibiting an enzyme unique to bacteria, or disrupting bacterial
protein synthesis.
Q6. What is a superinfection?
A. An infection that occurs before antibiotic therapy
